文献速递认知障碍与痴呆

唐氏综合征及Dp16模型中的逆转录体蛋白减少:APP基因剂量影响及γ-分泌酶调节剂的临床前研究

Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a γ-Secretase Modulator.
PubMed 文献 · Ann Neurol · 2023-04-29

本研究检测唐氏综合征(DS)及DS合并阿尔茨海默病(DS-AD)患者额叶皮层中逆转录体复合体组分水平,并在Dp16小鼠模型中验证。发现VPS26A、VPS26B和VPS29在DS和DS-AD中显著降低,且与APP基因剂量增加有关;γ-分泌酶调节剂(GSM;776890)治疗可完全防止逆转录体复合体减少。

要点

  • DS和DS-AD患者额叶皮层中VPS26A、VPS26B和VPS29显著降低,VPS35未降低。
  • Dp16老年小鼠(16月龄)脑内VPS26A、VPS26B和VPS29下调,且需要增加的App基因剂量。
  • GSM(776890)治疗完全防止了逆转录体复合体的减少。

核心结论

  • 研究提示增加的APP基因剂量损害DS中的逆转录体功能,并提示Aβ42和Aβ40的因果作用。

研究设计与样本

  • 检测DS-AD、DS及部分三体21(PT-DS,仅APP基因正常2拷贝)病例额叶皮层中逆转录体组分水平。
  • 分析Dp16小鼠模型脑内这些蛋白,并用γ-分泌酶调节剂(GSM;776890)处理Dp16小鼠以降低Aβ42和Aβ40水平。

主要发现

  • VPS26A、VPS26B和VPS29在DS和DS-AD中显著降低,但在PT-DS中未降低;VPS35未显著降低。
  • VPS26A、VPS26B和VPS29的下调在老年Dp16小鼠(16月龄)脑内重现,且需要增加的App基因剂量。
  • GSM治疗完全防止了逆转录体复合体的减少。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The retromer complex plays an essential role in intracellular endosomal sorting. Deficits in the retromer complex are linked to enhanced Aβ production. The levels of the components of the retromer complex are reported to be downregulated in Alzheimer disease (AD). Down syndrome (DS) shares neuropathological features with AD. Recent evidence points to dysregulation of the retromer complex in DS. The mechanisms underlying retromer deficits in DS and AD are poorly understood. METHODS: We measured the levels of retromer components in the frontal cortex of cases of DS-AD (AD in DS) as well as DS; the frontal cortex of a person partially trisomic (PT-DS) for human chromosome 21 (HSA21), whose genome had only the normal 2 copies of the APP gene, was also examined. We also analyzed these proteins in the Dp16 mouse model of DS. To further explore the molecular mechanism for changes in the retromer complex, we treated Dp16 mice with a γ-secretase modulator (GSM; 776890), a treatment that reduces the levels of Aβ42 and Aβ40. RESULTS: We found VPS26A, VPS26B, and VPS29, but not VPS35, were significantly reduced in both DS and DS-AD, but not in PT-DS. Downregulation of VPS26A, VPS26B, and VPS29 was recapitulated in the brains of old Dp16 mice (at 16 months of age) and required increased App gene dose. Significantly, GSM treatment completely prevented reductions of the retromer complex. INTERPRETATION: Our studies point to increased APP gene dose as a compromising retromer function in DS and suggest a causal role for Aβ42 and Aβ40. ANN NEUROL 2023;94:245-258.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Chen XQ, Sawa M, Becker A, et al. Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a γ-Secretase Modulator. Ann Neurol. 2023. PMID: 37042072. doi:10.1002/ana.26659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。